Clinical bottom line
Cerebral small vessel disease (CSVD) is a common contributor to cognitive decline and motor impairment in older adults, often manifesting as executive dysfunction, gait disturbances, and balance problems. Early intervention strategies targeting vascular risk factors, cognitive rehabilitation, and physical therapy show promise in mitigating progression of cognitive and motor symptoms, but robust clinical trial evidence remains limited. Clinicians should consider a multidisciplinary approach tailored to individual risk profiles and symptomatology, while recognizing that current evidence is largely hypothesis-generating and warrants further validation.
What the evidence shows
CSVD encompasses a spectrum of pathological changes affecting small cerebral arteries, arterioles, capillaries, and venules, leading to white matter lesions, lacunar infarcts, and microbleeds that underlie clinical symptoms (Ferro et al., 2014). Cognitive consequences predominantly involve executive dysfunction, slowed processing speed, and attention deficits rather than memory impairment typical of Alzheimer’s disease (Ferro et al., 2014; Uiterwijk et al., 2017). Motor symptoms include gait disturbances, impaired stance, and balance deficits, which increase fall risk and disability (Baezner et al., 2014).
Early intervention strategies focus on aggressive management of vascular risk factors such as hypertension, diabetes, and hyperlipidemia, which are strongly associated with CSVD progression (Uiterwijk et al., 2017; Li et al., 2025). Cognitive rehabilitation targeting executive function and attention has shown preliminary benefits in small cohorts, potentially improving daily functioning (Ferro et al., 2014). Physical therapy emphasizing balance and gait training may reduce motor impairment and fall risk, although high-quality randomized controlled trials are sparse (Baezner et al., 2014).
Emerging evidence suggests that some patients experience transient cognitive collapses linked to severe CSVD burden, a syndrome termed CSVD-ITCC, which may be reversible with optimized vascular and symptomatic management (A-Hakam et al., 2025). Genetic factors, including apolipoprotein E genotype, may modulate susceptibility and response to interventions, but clinical implications remain under investigation (Shams et al., 2020).
Neuropsychiatric symptoms such as depression and apathy frequently co-occur with CSVD and may exacerbate cognitive and motor dysfunction, highlighting the need for comprehensive assessment and integrated treatment approaches (Systematic Review, 2021).
Caveats and uncertainty
The heterogeneity of CSVD pathology and clinical presentation complicates standardized intervention protocols. Most evidence derives from observational studies, small interventional trials, or expert consensus rather than large-scale randomized controlled trials. The relative contribution of CSVD to cognitive and motor symptoms often overlaps with other neurodegenerative or vascular conditions, limiting specificity of treatment effects.
Longitudinal data on the durability of early interventions are limited, and optimal timing, intensity, and combination of therapies remain undefined. The role of novel biomarkers and neuroimaging in guiding personalized treatment strategies is promising but not yet established in routine clinical practice (Li et al., 2025).
Genetic and neuropsychiatric modifiers add complexity to management, and current interventions may not fully address these dimensions. The CSVD-ITCC syndrome is a novel concept requiring replication and validation before widespread clinical adoption (A-Hakam et al., 2025).
How this may change practice
Neurologists should maintain a high index of suspicion for CSVD in patients presenting with unexplained executive dysfunction, gait disturbances, or balance impairment, especially in the context of vascular risk factors. Early comprehensive assessment including neuroimaging and cognitive testing can facilitate timely diagnosis.
Management should prioritize rigorous control of vascular risk factors per current hypertension and diabetes guidelines, as these remain the cornerstone of slowing CSVD progression. Incorporation of cognitive rehabilitation and tailored physical therapy may enhance functional outcomes, although clinicians should counsel patients regarding the preliminary nature of evidence.
Multidisciplinary care involving neurology, rehabilitation, psychiatry, and primary care is advisable to address the multifaceted impact of CSVD, including neuropsychiatric symptoms. Awareness of emerging syndromes such as CSVD-ITCC may prompt consideration of reversible cognitive fluctuations in severe cases.
Future practice may integrate genetic and biomarker profiling to personalize interventions, but this remains investigational. Clinicians should remain updated on evolving evidence and participate in or refer patients to clinical trials evaluating early intervention strategies in CSVD.